Friday, December 6, 2024

Veractye DECIPHER Prostate Takes Gets Upgraded Status at NCCN

Medicare cover is often driven by positioning in NCCN guidelines.  On that score, a win on December 4, 2024, for Veracyte and its DECIPHER prostate recurrence risk test.

##

Medicare has covered prostate risk tests from Decipher, Myriad, and Genomic Health for a number of years.  At one point, they were near parity in Part B (based on annual, public claims data).  In the last couple years, in Part B, usage of the Decipher test has pulled ahead of the other two tests.  (Veracyte acquired Decipher in March 2021). 

##

Decipher Press release

  • Dec. 5, 2024-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the only gene expression test to be included in version 1 of the 2025 NCCN* Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as part of the updated “Advanced Tools” table located in the Principles of Risk Stratification and Biomarkers section (PROS-H) .
  • “The Decipher Prostate test’s performance and clinical utility have been demonstrated in many dozens of peer-reviewed, published studies, including analyses of samples from multiple prospective, Phase 3 clinical trials, making it the most validated test of its kind for prostate cancer,” said Phil Febbo, M.D., Veracyte’s chief scientific officer and chief medical officer. “We believe the Decipher Prostate test’s unique status in the NCCN guidelines stems from the evidence generated through our commitment to research and our numerous collaborations with leading prostate cancer researchers around the world.”
  • The Decipher Prostate test is a whole-transcriptome-derived, 22-gene signature that clinicians use to help assess the likelihood of a prostate tumor progressing to metastatic disease. Armed with this information, the clinician may recommend less-intensive or earlier, more-intensive treatment for the patient.
  • “The Decipher Prostate test is already the most widely used molecular test in prostate cancer. We believe its unique status in the updated NCCN guidelines will help make it more accessible to even more patients,” said Marc Stapley, Veracyte’s chief executive officer.
A Wall St report here.  On Yahoo Finance 12/6, Myriad is listed as down 11%, Veracute as up 3%.  (Both changes are in the neighborhood of $100M of market cap, Veracyte's market cap being roughly 3x ($3B vs $1B).


Where to Find It

Find the 223-page December 2024 NCCN Prostate Guideline (branded v1.2025) here:

Email registration required.

On page 62, Advanced Tools, lists Decipher gene expression test and Artera-AI slide imaging test for "Localized" prostate risk uses.  Only Decipher (aka 22 gene GC) is listed for "post-RP, post-radical-prostatectomy" risk.    

On the next page, Table 2 discussed Decipher in more detail.  On the next page after that, Table 3 discusses Artera AI in more detail.

Below, click to enlarge. 





Nerd Corner

Above are the 1.2025 version, just released.   Online at Pubmed I found Schaeffer et al., April 2024, Version 3.2024 (PMID 38626801).   This gave a different format, with more tests listed, of which only Decipher and Artera have Level 1 (1B) evidence in column 6.   Decipher and Artera survive in the update to 1.2025.   Here is 3.2024, click to enlarge.





Thursday, December 5, 2024

BLOODPAC: Webinar Held December 5, 2024, on ctDNA, Multiomics and AI

On December 5, 2024, BLOODPAC held a 2-hour, multi-speaker webinar on ctDNA, highlighting new trends in multiomics and AI.

Find BLOODPAC here.  The webinar will eventually be in a streaming archive, and a meeting report will be generated as well.  Their events archive is here.

##

Keynote speakers were:

  • Samir Hunash PhD, MD Anderson, proteins.
  • Wendy Winckler PhD, Droplet Biosciences, enhancing MRD and early detection.
  • Christopher Douville PhD, Johns Hopkins, LBx toolkit.
  • Robert Tell PhD, Tempus AI, leveraging multi-modal, multi-omic data streams
These speakers were followed by a panel, and then Q&A.

A TEMPUS slide characterized the difficulty of implementing an AI dream, which would cloud-integrate all sorts of diverse, siloed and longitundinal clinical and molecular data:

Tempus / Bloodpac / 1h9m


##

AI Corner (Chat GPT 4o)

Report on the "Beyond ctDNA: Towards the Integration of Multi-omics and Multimodal AI in Liquid Biopsy Assays" Seminar

Date: December 5, 2024
Duration: 2:00 PM - 4:00 PM ET
Host: BLOODPAC

The seminar, titled "Beyond ctDNA: Towards the Integration of Multi-omics and Multimodal AI in Liquid Biopsy Assays," convened leading experts in oncology, bioinformatics, and diagnostics to discuss advancements in multi-omics and AI applications in liquid biopsy technology. The event comprised a series of presentations, a panel discussion, and an interactive Q&A session.


Key Highlights

1. Introduction and Context

The seminar opened with remarks emphasizing the rapid advancements in liquid biopsy technologies, particularly the integration of multi-omics and multimodal data. The overarching goal was to explore how these innovations could enhance diagnostic precision and cancer treatment.


2. Presentations

2.1. Circulating Proteins for Cancer Risk Assessment
The first presentation focused on the use of circulating protein biomarkers for assessing cancer risk. The discussion included:

  • Development of multi-cancer screening panels incorporating protein markers.
  • Validation of markers like pro-surfactant B for lung cancer risk and its integration with imaging findings.
  • A trajectory-based approach to cancer risk detection, showcasing its potential to identify high-risk patients earlier.

2.2. Challenges Beyond ctDNA
This session addressed the limitations of circulating tumor DNA (ctDNA) in low-tumor-burden settings and proposed strategies to overcome these challenges:

  • Use of complementary analytes such as RNA, metabolites, and proteins.
  • Examples of assays improving sensitivity for early detection and post-operative monitoring, including lymphatic fluid analysis for head and neck cancers.

2.3. Analytical Toolkit for Liquid Biopsy Development
A detailed discussion on the statistical and computational methods used to evaluate candidate biomarkers, including:

  • Tools for detecting rare mutations, aneuploidy, and fragmentation patterns.
  • Strategies to mitigate overfitting in AI-based liquid biopsy models.

2.4. Multi-modal and Multi-omics Data Streams in Diagnostics
The final presentation highlighted the integration of multiple data streams:

  • Leveraging analytes like ctDNA, RNA, and proteomics with clinical data.
  • Challenges in managing and analyzing large-scale multimodal datasets within clinical timeframes.

3. Panel Discussion

The panel featured experts in bioinformatics, diagnostics, and AI, who discussed:

  • The future of multi-omics in personalized medicine.
  • Strategies for standardizing pre-analytics and data integration.
  • Insights into regulatory and logistical challenges in deploying these advanced diagnostics.

4. Q&A Session

The event concluded with a 20-minute Q&A session, during which participants posed questions about the practical applications and challenges of integrating multi-omics and AI into clinical workflows. Key topics included:

  • Enhancing biomarker validation across diverse populations.
  • Addressing pre-analytical variability in novel assays.
  • The role of collaboration between research institutions and industry in accelerating innovation.

Conclusions

The seminar underscored the transformative potential of combining multi-omics with AI to redefine liquid biopsy technologies. Presenters and panelists stressed the importance of interdisciplinary collaboration, robust data validation, and streamlined workflows to bring these innovations from research to clinical practice. The discussions reflected optimism for the future of precision oncology and its ability to improve patient outcomes through early detection and personalized care.

New FDA Guidances: (1) AI in Devices, (2) How FDA Writes Guidances

 

FDA has released a  new guidance for the use of AI in medical devices, and new guidance on best-practices for guidance.


AI in Medical Devices (PCCP)

Coverage at Forbes here.   Healthcare Dive here. The FDA document itself, is specific to: "predetermined change control plans (PCCPs)" for AI in medical devices.  (The draft had been issued 4/2023).

FDA thinking on PCCP in general, may be important for genomic tests as well, which are also frequently updated.


How FDA Writes Good Guidances

FDA has also released guidance, on how it writes guidances.  See AgencyIQ at LinkedIn here.   (They provide an open access 6p white paper).  And see the FDA home page for the topic, updated December 2, 2024 - here.  See the  December 3, 2024 Fed Reg notice, 89FR95799.  

See a 27 page draft report on "best practices" for guidances here.  See the final report here.  AgencyIQ, in their 6p white paper, warns the final report may fall short of industry expectations.





##
Separately, see a new Endpoints article on FDA guidance for accelerated drug withdrawals here.

##
AI Corner
Chat GPT 4 summarizes in 100 words or less.

##
The FDA's guidance on Predetermined Change Control Plans (PCCPs) for AI-enabled medical devices provides a framework to support iterative improvements while ensuring safety and effectiveness. PCCPs outline planned modifications, methods for validation, and risk assessments. Once a PCCP is authorized, manufacturers can implement changes without additional marketing submissions, provided they follow the approved protocol. This approach aims to streamline updates, encourage innovation, and maintain regulatory compliance. 

Key components include descriptions of modifications, modification protocols, and impact assessments. The FDA emphasizes quality system adherence, transparency in device labeling, and encourages early engagement through the Q-Submission Program to refine PCCPs.

##
The FDA's "Report and Plan on Best Practices for Guidance" outlines strategies to enhance transparency, consistency, and efficiency in guidance document creation and use. Key elements include standardizing formats, improving public comment processes, and utilizing technology for better communication. The FDA aims to streamline regulatory submissions and make guidance documents accessible and responsive to evolving scientific and public health needs. Public input is prioritized for Level 1 guidance, except in urgent cases, while outreach via various platforms ensures broad accessibility. Periodic reviews will assess the relevance of guidance, maintaining alignment with current regulatory and public health priorities.
  • Level 1 Guidance: Addresses new or significant interpretations of laws/regulations, policy changes, complex scientific issues, or controversial topics. It requires more rigorous internal review and public comment before finalization.
  • Level 2 Guidance: Focuses on existing practices, minor policy clarifications, or technical corrections. It has simpler procedures, often skipping extensive reviews and public comment, making it faster to develop and issue.

##
Agency IQ (6 page white paper)

Per AgencyIQ, the FDA's final report on guidance development outlines plans to enhance transparency, efficiency, and stakeholder engagement. Key initiatives include updating the Good Guidance Practices (GGP) regulation to align with modern technology, streamlining comment processes, and improving guidance accessibility through expanded online resources. Specific changes involve standardized formats, line-numbered drafts, and expanded guidance agendas, including for the Oncology Center of Excellence. While incorporating some stakeholder suggestions, the FDA's report largely focuses on its internal priorities, leaving many industry requests unmet. Future regulatory updates to the GGP regulation may provide additional opportunities for stakeholder input on improving the guidance

#
What industry needs were unmet?

According to AgencyIQ, the FDA’s final report on guidance documents left several industry needs unmet, including:

  1. Standardized Templates: Industry requested a universal template for all FDA guidance documents to improve consistency and clarity. This was rejected due to the diverse needs of different Centers.

  2. Detailed Comment Summaries: Stakeholders sought comprehensive summaries of FDA’s responses to public comments on guidance documents, which were not incorporated.

  3. User-Friendly Access: Suggestions to create centralized, easy-to-download folders of stakeholder comments or maintain a single webpage listing all withdrawn guidance documents were declined.

  4. Flexible Formats: Requests to use non-PDF formats, such as web-based or interactive guidance documents, were ignored, maintaining the current reliance on PDF.

  5. Greater Responsiveness: Stakeholders highlighted the need for the FDA to adapt lessons from the COVID-19 pandemic, such as faster guidance dissemination, for non-emergency contexts. This was not reflected in the final report.

  6. Broader Use of Level 2 Guidance: While Level 2 documents are easier to develop, FDA limited their use, frustrating those seeking a more flexible and rapid guidance process.

  7. Expanded Public Input: Calls for broader mechanisms to influence guidance development or suggest revisions were only partially addressed with minimal procedural updates.

These omissions reflect the FDA's focus on internal efficiency and priorities rather than fully addressing stakeholder-driven reforms





Wednesday, December 4, 2024

JAMA Articles Highlight Massive Molecular UTI Testing in Medicare - MolDx Got There First

This week, JAMA has two articles discussing a recent "boom" in molecular UTI testing.  The articles were highlighted in Genomeweb.    Notably, over the past couple years, the MolDx program saw a "boom" in molecular pathogen testing several years ago, and brought out a strictly-limited LCD on the topic, including blocking most molecular testing on routine UTIs.

###

###

The JAMA articles are worthwhile reading.   Neither Hatfield or Fitzpatrick pick up on another track of the story, which was LCD respones and 180 degree turnarounds in the payment velocity.  I believe this would have been most striking in MolDx policy regions.   More about MolDx, next.

###

MolDx noted an explosion in molecular pathogen codes (including one for "other pathogen" billed in high multiples) several years ago.   The responded with a strict LCD, a voluminous billing and coding article, and even a Palmetto website FAQ.   These policy activiites led to a marked drop in payments for the now-controlled codes in MolDx regions (28 states).

  • Find the FAQ here.
  • Find the LCD here.
  • Find the billing/coding article here.
  • Anticipating requests for coverage based on prior literature, MolDx even published a 9-page PDF of hundreds of molecular UTI articles that "HAVE NOT adequately met the clinical validity and clinical utility criteria for UTI panels."   Here.
If I recall correctly, early versions of the LCD focused on CPT panel codes (e.g. a single code for "pulmonary pathogen x 12") and did not control alternative billing tricks, like the same test coded creatively as "other pathogen" which is then billed x12.

##

While the work of Hatfield et al is important, leading to a JAMA publication with high visibility, I'd also note that much of the data is not secret, but is published annually and openly by CMS, so that anyone in the public could also have tracked the explosive growth in these codes in a matter of an hour or two.  (An example from my own work here.)   The Hatfield work had a higher level of specificity, by pairing pathogen procedures with UTI ICD-10 codes, which requires researcher-level access.   But the take-home lesson which is massive payment growth on uncontrolled codes would be publicly available.

##

You can also identify the specific labs that were billing some of these codes, and how much they were paid per year, in a CMS public data source here.



Monday, December 2, 2024

Now Online: The Closing Briefs in FDA LDT Lawsuit (ACLA, AMP)

Thanks to CAP Advocacy News for providing links to final closing briefs newly filed by ACLA and AMP in the FDA LDT court case.

https://documents.cap.org/documents/acla-closing-brief2024.pdf

https://documents.cap.org/documents/amp-closing-brief2024.pdf

They weigh in at 32pp and 34pp, respectively, dated-stamped 11-25-2024.

The AMP brief discusses MolDx (p. 20).  

ACLA writes (p2) "Unable to defend the agency's untenable position, FDA's lawyers double down on a strategy of obfuscation and definitional sleight of hand."

They note that 1976 device law specific limited FDA control to "devices" and "in vitro reagents" [less than a device], and not "processes" like LDTs.

They emphasize than at LDT is not an object or item placed into interstate commerce.  They distinguish lab procedures from software (SaMD) because software is actually tangible, e.g., a downloaded computer file transferred from one place to another [w/ citations to court cases on SaMD].

Much is made of the legislative intent of CLIA vs FDA; CLIA specifically allows for FDA IVD's to be modified and become LDTs under CLIA; that ability doesn't make sense if it is simultaneously illegal to do so under FDA law.

##

[Particularly colorful is the ACLA's 9/2024, 51-page entertaining and lively motion for summary judgement including their hatchet job on FDA's attempts to defend itself - here.  Discussed at bottom of blog.]

##

AI Corner - Chat GPT 4o

Summary Argument: 

FDA’s Overreach on Laboratory-Developed Tests (LDTs)

Introduction: A Health Law Perspective

The U.S. Food and Drug Administration (FDA) has overstepped its statutory authority by asserting that Laboratory-Developed Tests (LDTs) constitute "medical devices" under the Federal Food, Drug, and Cosmetic Act (FDCA). This unprecedented move disrupts decades of regulation under the Clinical Laboratory Improvement Amendments (CLIA), which govern laboratory services as professional healthcare activities. The FDA’s Final Rule embodies what legal scholars term a “major questions” case—an agency claiming vast, newfound authority with no clear Congressional mandate. This interpretation risks undermining medical innovation and threatening access to vital diagnostic services​.

Key Legal and Regulatory Issues

  1. Misinterpretation of "Device": The FDCA defines a device as a tangible, manufactured product intended for use in medical contexts. FDA's attempt to include intangible testing procedures or protocols under this definition stretches the statutory language beyond recognition. Laboratory protocols are services, not manufactured goods, and cannot reasonably be categorized as "devices"​.

  2. Violation of the Commercial Distribution Requirement: LDTs are created and used within a single laboratory, lacking the commercial distribution element required under FDCA’s regulatory scope. By targeting these tests, the FDA misrepresents the statutory requirement for regulating goods in interstate commerce​.

  3. CLIA’s Authority over LDTs: Congress explicitly designated CLIA as the regulatory framework for laboratory services, focusing on accuracy and reliability through licensure and professional oversight. FDA's encroachment disregards this statutory division, conflating manufacturing oversight with clinical practice regulation​.

FDA’s Deficient Legal Justifications

FDA’s arguments rely on definitional manipulation and unsupported analogies:

  • Redefining "Manufacturing": FDA contends that developing or using testing protocols equates to manufacturing a device. This conflation ignores that protocols do not create a tangible product; they represent professional expertise and procedural development​.
  • Shifting Interpretations: FDA asserts that it has historically claimed authority over LDTs since the 1970s, yet this claim lacks enforcement history. Courts should not legitimize what amounts to "regulatory adverse possession"—an agency retroactively asserting long-dormant authority​.

Major Questions Doctrine

The Supreme Court has consistently held that transformative regulatory claims require explicit Congressional authorization. FDA’s assertion fails this test:

  • Economic and Professional Impact: The rule disrupts a significant healthcare sector, imposing billions in compliance costs while criminalizing longstanding medical practices​.
  • Legislative Silence: Congress has repeatedly declined to grant FDA authority over LDTs, further highlighting the agency’s overreach​.

Arbitrary and Capricious Rulemaking

FDA's reliance on non-binding “enforcement discretion” policies demonstrates the weakness of its legal interpretation. By admitting that laboratories could be prosecuted at any time for routine activities, FDA injects uncertainty into essential diagnostic services. This ambiguity underscores the arbitrary nature of the Final Rule​.

Conclusion

FDA’s Final Rule represents a sweeping and legally unfounded attempt to regulate professional healthcare services as if they were manufactured goods. By conflating laboratory-developed protocols with tangible devices, the agency jeopardizes patient care, medical innovation, and the integrity of administrative law. Courts must vacate this rule, as it exceeds statutory limits, disregards Congressional intent, and undermines the longstanding division between CLIA and FDCA authority.

As the plaintiffs aptly summarize: “Unable to defend the agency's untenable position, FDA's lawyers double down on a strategy of obfuscation and definitional sleight of hand.” \

This Court should reject this overreach to preserve the integrity of laboratory services​.


##


AI Corner (Chat GPT 4o)

ACLA Closing Brief

The American Clinical Laboratory Association (ACLA)'s closing brief presents a robust critique of the FDA's final rule, centered on the legal interpretation of whether laboratory-developed tests (LDTs) and testing protocols constitute "devices" under the Federal Food, Drug, and Cosmetic Act (FDCA). 

Key Arguments from the ACLA Brief

  1. Definition of a Device:
    ACLA argues that the FDCA's definition of a "device" is limited to tangible, manufactured products, such as instruments or test kits. Laboratory testing protocols, by contrast, involve professional services and the use of physical tools but do not constitute a "device" themselves. The brief emphasizes the inconsistency of FDA's claims with statutory language and historical interpretation of the FDCA.

  2. CLIA vs. FDCA Jurisdiction:
    ACLA asserts that the Clinical Laboratory Improvement Amendments (CLIA) already provide a comprehensive regulatory framework for laboratory services, focusing on analytical and clinical validity. CLIA's regulatory scope, combined with its professional licensing standards, highlights the professional-service nature of LDTs, further distinguishing them from the FDA-regulated manufacturing of devices.

  3. Major Questions Doctrine:
    The brief invokes the doctrine to argue that the FDA's reinterpretation of its authority to regulate LDTs represents a "transformative" change that lacks explicit Congressional authorization. Such a significant expansion of regulatory scope requires clear statutory language, which is absent here.

  4. Economic and Practical Impacts:
    ACLA critiques the rule as imposing massive compliance costs and regulatory burdens on laboratories, disrupting established practices. The brief points out that FDA's own carveouts and "enforcement discretion" policies demonstrate the impracticality and overreach of its interpretation.

  5. Ad Hoc Enforcement Policies:
    The brief challenges FDA's reliance on non-binding enforcement discretion to mitigate the rule's harsh impacts, calling it arbitrary and an acknowledgment of the rule's flaws.

Analysis and Insights

  • Tangible vs. Intangible:
    A central theme in ACLA's argument is the distinction between tangible goods (e.g., test kits) and professional services. This distinction is crucial for laboratories to argue that the development of LDTs involves the application of expertise and established protocols, not the creation of new devices.

  • Historical and Statutory Context:
    By contrasting the FDA's current claims with decades of regulatory practice, ACLA underscores the absence of precedent for treating laboratory protocols as devices. This lends credibility to its assertion that FDA's action is a regulatory overreach.

  • Broader Implications for the Lab Industry:
    If the FDA's final rule stands, laboratories may face dual regulatory burdens under CLIA and the FDCA, leading to increased costs and delayed innovation. This could particularly impact smaller labs and their ability to offer customized tests for unique clinical needs.

Takeaway for the Lab Industry

  • Regulatory Advocacy: Laboratories must actively engage in the regulatory process, emphasizing the professional nature of their work and the existing adequacy of CLIA oversight.
  • Compliance Strategy: Lab directors should prepare for potential changes by evaluating their current practices in light of FDA's final rule while also contributing to industry efforts to challenge or clarify regulatory boundaries.
  • Legal Vigilance: The use of doctrines like major questions and rule of lenity reflects the high stakes and legal complexity of this issue, suggesting a need for continued monitoring of judicial outcomes.

ACLA's brief frames a compelling argument for rejecting FDA's final rule, portraying it as an unlawful expansion of authority with significant adverse consequences for the lab industry. The industry should draw on these arguments to advocate for clear and practical regulatory distinctions between devices and professional laboratory services.


##

AMP


Review of the AMP Closing Brief

The Association for Molecular Pathology (AMP)'s closing brief offers a detailed critique of the FDA’s final rule asserting regulatory authority over laboratory-developed tests (LDTs). 


Key Arguments from the AMP Brief

  1. Major Questions Doctrine:

    • Unprecedented Scope: AMP argues that the FDA’s claim to regulate LDTs under the FDCA invokes the “major questions doctrine,” requiring clear Congressional authorization. The brief emphasizes that the FDA has overstepped by attempting to regulate an area traditionally left to CLIA and professional discretion.
    • Economic and Political Significance: AMP underscores that subjecting LDTs to FDA regulation will impose extraordinary costs (estimated in billions) and stifle innovation, directly impacting patient care. Congress has repeatedly declined to authorize such regulation, highlighting the legislative void.
  2. Conflict with FDCA:

    • Definition of a Device: AMP asserts that LDTs, which involve professional services rather than tangible, commercial products, fall outside the statutory definition of a "device" under the FDCA.
    • Commercial Distribution Requirement: LDTs are developed and used within the same lab, without being distributed commercially. AMP argues that the FDA’s attempt to apply the FDCA to non-commercial activities misinterprets the statute.
    • Practice of Medicine Exemption: The brief highlights statutory protections for healthcare practitioners under the FDCA, asserting that the FDA’s rule violates these exemptions by penalizing laboratories for using and modifying diagnostic tools.
  3. CLIA vs. FDCA Jurisdiction:

    • Separate Regulatory Schemes: AMP contends that Congress designed CLIA to oversee the quality and validity of laboratory tests, including LDTs, making FDA oversight duplicative and unnecessary. The brief highlights that CLIA already ensures analytical and clinical validity through proficiency testing and quality controls.
    • No Overlap in Authority: AMP emphasizes that FDA's regulation of LDTs would disrupt CLIA’s comprehensive framework, creating regulatory conflicts that Congress never intended.
  4. Arbitrary and Capricious Rulemaking:

    • Lack of Evidence: AMP critiques the FDA for failing to provide adequate justification for the rule, particularly in light of the agency’s historical non-enforcement and the existing oversight under CLIA.
    • Economic Burden: The brief emphasizes the disproportionate costs of the rule, which would force laboratories to abandon innovative tests, disrupt patient care, and overburden the FDA itself with regulatory demands.

Analysis and Insights

  • The Legal Foundation of LDTs as Professional Services:

    • AMP effectively distinguishes LDTs from commercial devices by framing them as integral to the practice of medicine. This argument positions laboratories as extensions of clinical decision-making rather than as manufacturers of products.
  • Historical and Statutory Context:

    • By referencing Congress’s repeated refusal to grant FDA authority over LDTs, AMP strengthens its claim that the FDA’s final rule lacks statutory support. The reliance on legislative history and previous regulatory practice supports AMP’s interpretation of Congressional intent.
  • Regulatory Overlap Between CLIA and FDA:

    • The brief convincingly argues that CLIA adequately regulates the reliability and safety of LDTs. AMP’s position that FDA oversight would disrupt existing processes resonates with stakeholders wary of redundant regulation.
  • Economic and Practical Consequences:

    • AMP’s detailed cost analysis highlights the real-world implications of FDA overreach. The estimated financial burden and potential harm to patient access and innovation amplify the argument that FDA regulation is unjustified.

Takeaway for the Lab Industry

  • Advocacy for Legislative Clarity: The lab industry should continue to advocate for clear statutory boundaries, emphasizing the professional and non-commercial nature of LDTs.
  • Collaboration with CLIA: Laboratories should highlight the efficacy of CLIA’s regulatory framework in ensuring test quality, while showcasing its flexibility for innovation.
  • Preparing for Potential Changes: Even as AMP’s arguments challenge the FDA’s authority, laboratories should assess compliance strategies in the event of regulatory shifts, while supporting industry-wide litigation efforts.

The AMP brief underscores a cohesive argument against FDA overreach, emphasizing the role of LDTs in advancing patient care under existing CLIA oversight. Its detailed analysis provides a strong foundation for resisting the final rule, with significant implications for the lab industry.


##

Here is the September 2024 ACLA motion for summary judgment, MSJ, which seems more legalistic than the closing memoradum.   Discuss?

The ACLA’s Motion for Summary Judgment is indeed more detailed and legalistic than the ACLA’s Closing Brief, which is consistent with their distinct purposes. Below is a detailed comparison and analysis based on the content of the Motion for Summary Judgment (MSJ):


Nature of the Motion for Summary Judgment (MSJ)

The Motion for Summary Judgment is a legal document filed mid-case to argue that the court should rule in the plaintiff's favor on specific issues because there are no disputed material facts requiring a trial. It is highly focused on statutory interpretation, precedent, and administrative law principles, often citing detailed legal authorities to demonstrate why the agency’s actions are invalid.


Comparison of Content with the Closing Brief

  1. Legalistic Framework and Depth of Analysis:

    • The MSJ engages deeply with the statutory text, legislative history, and judicial precedent, often invoking specific Supreme Court cases (e.g., West Virginia v. EPA, FDA v. Brown & Williamson Tobacco Corp.) and applying principles like the major questions doctrine.
    • The Closing Brief, while still grounded in legal arguments, is broader and more rhetorically persuasive, summarizing key arguments made earlier in the litigation and focusing on policy impacts and the broader narrative of FDA overreach.
  2. Focus on Administrative Procedure Act (APA) Violations:

    • The MSJ details the procedural flaws in the FDA’s rulemaking, including its failure to justify the rule adequately under the APA. It heavily critiques the FDA’s reliance on "enforcement discretion" to defend its regulation, arguing that this creates arbitrary and capricious standards.
    • The Closing Brief mentions APA violations but in a more summary fashion, emphasizing their impact on the laboratory industry rather than the technicalities of administrative law.
  3. Reliance Interests and Economic Analysis:

    • The MSJ emphasizes reliance interests, discussing how laboratories, clinicians, and patients have operated under CLIA’s framework for decades. It quantifies the economic burden of the FDA’s rule (e.g., billions in compliance costs, reduction in test availability).
    • The Closing Brief simplifies these arguments for persuasive effect, using them as evidence of the rule's impracticality.
  4. Statutory Interpretation:

    • The MSJ dedicates substantial effort to dissecting the FDCA’s definition of “device” and arguing that laboratory-developed tests (LDTs) are professional services, not tangible products. It also critiques the FDA’s use of enforcement discretion as a means to bypass statutory limits.
    • The Closing Brief echoes these points but frames them in the context of broader consequences for the healthcare system.
  5. Major Questions Doctrine:

    • The MSJ elaborates extensively on this doctrine, arguing that the FDA’s rule represents a transformative expansion of authority without clear Congressional authorization, making it a textbook case for judicial skepticism.
    • The Closing Brief includes this argument but with less technical analysis, focusing on the doctrine's broader implications for agency overreach.

Notable Legalistic Features in the MSJ

  • Specific Legal Citations: The MSJ cites over 50 cases, statutes, and regulatory texts to support its arguments, demonstrating a meticulous legal foundation.
  • Detailed Legislative History: It reviews decades of legislative efforts (e.g., failed attempts to pass the VALID Act) to argue that Congress deliberately chose not to grant FDA authority over LDTs.
  • Analytical Structure: The MSJ breaks arguments into fine-grained subpoints (e.g., textual interpretation, legislative intent, reliance interests), providing a systematic roadmap for the court.

Conclusion

The ACLA’s Motion for Summary Judgment is substantially more legalistic, detailed, and technical than its Closing Brief. While the Closing Brief synthesizes and highlights key arguments for persuasive effect, the MSJ digs deeply into the statutory, procedural, and doctrinal aspects of the case to build a strong foundation for judicial review. This depth is necessary at the summary judgment stage to demonstrate that the facts and law conclusively favor the plaintiff without requiring a trial.


###

If the ACLA argues that a device must be a tangible, physical product, where does that leave a separate topic, the FDA's extensive regulation of software as a medical device?   This isn't of issue to ACLA, but it would be salient to a judge or FDA.

The FDA’s extensive regulation of Software as a Medical Device (SaMD) presents a potential counterpoint to the ACLA’s argument that a “device” under the FDCA must be a tangible, physical product. This issue, while not directly addressed by ACLA, could be salient for a judge or the FDA as it relates to the broader interpretation of the FDCA’s scope. Here’s an analysis of how this might influence the case:


1. FDA’s Approach to Software as a Medical Device

The FDA has long regulated certain types of software as medical devices, particularly under its SaMD framework, which encompasses:

  • Standalone software designed to diagnose, treat, or prevent disease.
  • Clinical decision support systems (CDSS), when they meet the FDCA’s definition of a device.

This regulatory framework has been upheld because software, although intangible, can have medical functionality comparable to traditional devices. Courts and regulators have accepted this broader interpretation of “device” under the FDCA when it aligns with the statute’s purpose of protecting public health.


2. Potential FDA Argument Based on SaMD Precedent

The FDA could argue:

  • Functional Equivalence: Like SaMD, LDTs may not be tangible products, but their functions—diagnosing or guiding treatment—align with the FDCA’s purpose to regulate devices that impact patient care.
  • Broad Definition of “Device”: The FDCA defines a device as an “instrument, apparatus, implement, machine, contrivance...or other similar or related article,” which could encompass intangible processes or services if they perform equivalent functions to regulated devices.
  • Precedent for Intangible Products: The regulation of SaMD demonstrates that the FDCA is not limited to physical, tangible items.

3. Distinction Between SaMD and LDTs

ACLA could counter this argument by emphasizing distinctions between SaMD and LDTs:

  • Tangible Input: SaMD often operates on tangible data from physical devices (e.g., imaging systems, wearables). LDTs, however, involve laboratory protocols applied to patient samples, aligning more closely with professional services.
  • Service vs. Product: LDTs are embedded in laboratory services and involve clinical expertise, making them fundamentally different from standalone software products designed for commercial use.
  • Historical Scope of Regulation: Unlike SaMD, which has been explicitly addressed in FDA guidance and international standards (e.g., IMDRF SaMD documents), LDTs have been historically regulated under CLIA as professional services, not devices.

4. Judicial Considerations

A judge might consider:

  • Consistency in Regulation: Does regulating LDTs as devices create inconsistencies with FDA’s approach to SaMD or does it harmonize with the broader regulatory framework?
  • Legislative Intent: The FDCA’s application to SaMD has been accepted partly because software serves as a direct surrogate for traditional devices. Does Congress intend the same logic to apply to LDTs, which have historically been treated as professional services?
  • Regulatory Overreach: Courts have upheld SaMD regulation within limits. However, applying the SaMD analogy to LDTs might be seen as overreach, particularly if it conflicts with CLIA and established reliance interests.

Conclusion

While the FDA’s regulation of SaMD provides a precedent for applying the FDCA to intangible products, LDTs are distinguishable as professional services rather than products. This distinction may allow ACLA to argue that the functional equivalence between SaMD and tangible devices does not extend to LDTs. However, judges may find the SaMD precedent persuasive if they adopt a broader view of the FDCA’s scope, potentially creating a challenge for ACLA’s narrower, tangible-product interpretation of “device.”


CAP Asks FDA a Question about LDT Rule; The Missing Key Answer

 College of American Pathologists publishes a newsletter about advocacy issues, which is open-access.  Here, they asked FDA a question about LDTs that appear after the issuance date of the rule (after May 2024).

CAP NEWSLETTER LINK

The CAP question is,

There is confusion about the regulatory obligations for LDTs developed after the issuance dates. We have received many questions about how to classify the tests, what documentation is needed, and can laboratories bring these systems online now.

##

FDA gives the CAP a completely boilerplate (pro forma) answer about general device classificatioin - PMA, 510k, etc.  

The FDA didn't even answer what I took to be the main point of the question [issuance date].  In general, LDTs before June 2024 must comply with paperwork rules in 2025, 2026, but no PMA/510k.  LDTs launched after June 2024 must comply with those paperwork rules PLUS PMA/510k.    

###

Here's the interesting answer, for me.  Tests around before May 2024 are "grandfathered" except for various requirements in May 2025, May 2026, and May 2027.  Then come the deadlines for actual PMA/510k filing.  If those documents are filed, FDA will allow tests to remain on the market until the documents are reviewed (anticipated a backlog approaching infinity).   That's filing PMA by November 2027, or 510k by May 2018.

Here's what's interesting.  If your PMA or 510k is filed later, like June 2018, you can't stay on the market (since you don't have on-file PMA or 510k by the staged deadlines), and, your PMA or 510k will be reviewed - god knows when, since it will be queued behind howeer many 10,000, or 50,000, PMAs or 510ks that the FDA lacks the staff to process.   So an LDT with paperwork filed in, say, June 2018, would be allowed for use....ever?  never?   2028?





ADVAMED Supports Bipartisan Senate Bill: Breakthrough Device Coverage at CMS


ADVAMED supports a bipartisan Senate bill to support Medicare coverage of FDA-reviewed Breakthrough products.

The Senate bill, from Sen. Todd Young (R IN) and Sen. Alex Padilla (D CA), parallels HR 1691, which passed the House Ways and Means committee in June 2024.

In a nutshell, the bill would restore the short-lived "MCIT" policy at the end of the "Trump I" administration, which was replaced by a much weaker "TCET" policy during the Biden administration.

Read more about the ADVAMED position here:

https://www.advamed.org/industry-updates/news/advamed-welcomes-bipartisan-senate-bill-to-expedite-medicare-coverage-of-breakthrough-medical-technologies-diagnostic-tests/?utm_source=chatgpt.com

##

June 2024 press release on House bill HR 1691, from ADVAMED.

The  committee bill passed by 36 yeas, 5 nays.

The bill contains a clause that CMS is not blocked from affecting coverage if the device is shown to have no benefit (or to have harms) to Medicare beneficiaries.   There is a special category called "specified breakthrough device" [SBTD] which is one with no prior benefit category.  SBTD's get special reports-to-congress.  The June 2024 House passage refers to amendments, but the Congress.gov home page doesn't list any.

Sunday, December 1, 2024

Brief Blog; FDA Posts Final Guidance re ctDNA in Drug Development

 FDA posts 20 page finao guidance on use of ctDNA as a biomarker in drug development.

See the 20 page PDF here:

https://www.fda.gov/media/183874/download

See an essay from Josie Hayes at Linked In here:

https://www.linkedin.com/posts/josie-hayes-phd-pccc_ctdna-drugdevelopment-fdaguidance-activity-7268283780929392642-8Xk-/?utm_source=share&utm_medium=member_ios

And subscription coverage at Genomeweb here.

"Big Three" Use Cases

The guidance encompasses "the big three" use cases - ctDNA for oncogene selection; for MRD; and for drug response.   For MRD, the FDA notes that tumor-informed and tumor-naive methods have various advantages.

###

AI Corner (Chat GPT 4o)

FDA's Draft Guidance on ctDNA in Drug Development

The FDA's November 2024 Draft Guidance focuses on using circulating tumor DNA (ctDNA) as a biomarker in curative-intent drug development for early-stage solid tumors. It highlights key roles for ctDNA, including patient selection, molecular residual disease (MRD) enrichment, response measurement, and early endpoints in clinical trials. This framework is part of the FDA's ongoing effort to improve precision in oncology and reduce treatment toxicity for patients unlikely to benefit from therapy.

Key Points and Takeaways:

  • Comment Period: The guidance allows a 60-day comment period for industry feedback.
    • [About January 20]
  • ctDNA in Trials:
    1. Can be used to select patients with specific molecular alterations, especially when tumor tissue is unavailable.
    2. MRD detection via ctDNA identifies patients at high risk of recurrence, enabling tailored escalation or de-escalation of therapy.
    3. ctDNA trends (e.g., clearance or reduction) could act as surrogate early endpoints, potentially predicting long-term outcomes like disease-free survival (DFS) or overall survival (OS).
  • Validation and Standardization:
    • Robust assay validation (e.g., sensitivity, specificity) is critical for regulatory acceptance.
    • [For MRD] Tumor-informed (mutation-specific) and tumor-naïve (general panel) assays each have advantages and limitations, depending on the study design.
  • Regulatory Synergy:
    • Emphasizes harmonization between ctDNA assays and broader regulatory requirements for investigational devices.

Broader Context: FDA and MRD Testing

  • The guidance builds on the FDA's 2020 Hematologic Malignancies Guidance, where MRD was validated in blood cancers. Applying similar principles to solid tumors remains a challenge due to variable ctDNA levels influenced by tumor type, stage, and biology.
  • For drug development, ctDNA could complement imaging or pathological assessments, streamlining early signals of efficacy in trials.

Final Thought:

The draft highlights the FDA's cautious optimism for ctDNA as a transformative biomarker in oncology, but it underscores the need for robust clinical evidence and assay consistency before ctDNA can achieve routine regulatory and clinical utility. Experts should consider contributing comments during the review window to refine these pivotal recommendations.

Brief Blog: BloodPac Webinar on Thursday December 5, 2024

 Watch for a new BLOODPAC  seminar, the Third Annual New Frontiers seminar.  This one is called, "Beyod ctDNA: Multiomics and Multimodal AI in Liquid Biopsy."   (And arriving just when you thought you had figured out ddPCR).   

It's 2-4pm ET on Thursday December 5.   11-1 PT.

https://www.eventbrite.com/e/bloodpac-2024-new-frontiers-seminar-tickets-1055858383849?aff=oddtdtcreator



Saturday, November 30, 2024

New Celebrity Interviews with the Late Michael Parkinson - via AI

Header: In a break from US health news, learn all about the late U.K. broadcaster who is coming back via  AI.

###



Outside of health technology news...

The Economist listed its "Best of 2024," including the category Podcasts, one of which was, "The Rest is Entertainment," in which Richard Osman just discussed his upcoming interview with Michael Parkinson.

Parkinson, as big a figure in the UK as Johnny Carson, Jay Leno, David Letterman in the US, died two years ago at age 88.   

His son, Mike Parkinson, manages the enormous video estate, which now collaborates with an AI company to recreate Michael Parkinson in real time.  Within a few months, an initial series of 8 interviews between AI-Parkinson and Livng-Celebrities will be released.

Read more about it at the sources below.  At bottom, my "AI Corner" discusses.

###

  • Michael Parkinson at Wikipedia.
  • Interview with his son Mike Parkinson here.
  • About the AI project - press release.
  • Coverage at, The Guardian.
  • Episode at "The Rest is Entertainment," Marina Hyde and Richard Osman, here.
    • AI Corner: At this link, two Google-AI voices discuss the news story (here).
    • (Open access, but requires a Google sign-in.)

###



AI Corner

AI discusses the above links [Chat GPT 4o].

##

The Digital Revival: Virtually Parkinson and the AI Reimagining of an Icon

The world of entertainment and artificial intelligence is colliding in fascinating ways, and few projects exemplify this better than the upcoming podcast Virtually Parkinson. An AI recreation of the late Sir Michael Parkinson will host a new generation of conversations, drawing upon the rich legacy of the man once hailed as Britain’s foremost interviewer. This innovative podcast promises not only to entertain but also to spark deeper discussions about the role of AI in preserving cultural icons.

The Concept Behind Virtually Parkinson

The podcast, spearheaded by Deep Fusion Films, will be divided into three parts. First, the guest and host discuss the implications of AI, touching on its capabilities and ethics. In the second segment, the AI version of Michael Parkinson takes the lead, conducting a classic one-on-one interview in the style that endeared him to millions. Finally, the guest and producers debrief, reflecting on the surreal yet thought-provoking experience.

This format allows the project to be more than a nostalgic tribute. It becomes a dialogue about human connection, authenticity, and the evolving interface between technology and culture.

The Making of AI Michael Parkinson

Deep Fusion Films collaborated closely with the Parkinson family and estate to ensure authenticity and ethical boundaries. AI Michael was created using advanced machine learning, trained on thousands of hours of Parkinson's original interviews. The result is an eerily lifelike replication—not just of his voice, but of his pacing, tone, and conversational style.

  • This isn't just a collection of sound bites; it's entirely new content, crafted by the AI in real-time during the interviews. 
  • It’s a cutting-edge way to revisit Parkinson’s style, showcasing his legendary ability to listen, engage, and unearth the most compelling stories from his guests.

Richard Osman and the AI Experience

Richard Osman, the noted author and TV presenter, is set to be one of the first guests on Virtually Parkinson. In a recent podcast, Osman shared his initial hesitation about appearing on the show, describing his unease upon hearing an AI-generated invitation from Michael Parkinson. However, after learning more about the project’s thoughtful approach, Osman reconsidered, intrigued by its potential to explore what it means to interact with an AI personality.

Osman’s upcoming episode will likely highlight the layered experience of conversing with an AI version of a beloved figure. The podcast’s creators hope that moments like these will inspire curiosity and conversation about the intersection of humanity and artificial intelligence.

Ethical Considerations and Legacy Preservation

The Parkinson family played an integral role in shaping this project, ensuring that their father's legacy was honored. Mike Parkinson, Sir Michael’s son, emphasized that the podcast isn’t just a commercial venture—it’s a tribute. The aim is to introduce new audiences to Parkinson’s unparalleled interviewing style while providing a thoughtful exploration of AI's role in storytelling.

The project raises important questions: Should we bring back iconic voices through AI? What are the boundaries of consent and ethical responsibility? The creators’ commitment to transparency—explicitly labeling the AI-generated nature of the host and consulting with the estate—sets a benchmark for similar ventures.

Looking Forward: Entertainment and AI

Virtually Parkinson is not just a podcast; it’s a cultural experiment. As AI continues to evolve, the entertainment industry faces exciting yet complex challenges. This podcast exemplifies how AI can be used to celebrate and extend legacies while prompting necessary debates about authenticity, creativity, and ethics.

Whether you’re a longtime admirer of Sir Michael Parkinson or simply curious about the possibilities of AI, Virtually Parkinson promises to be a landmark in digital innovation. It invites us all to ponder: What does it mean to preserve human legacy in an age where technology can recreate it?



FAQ [Google Notebook LM]

1. What is "Virtually Parkinson"?

"Virtually Parkinson" is a new 8-part podcast series featuring an AI replica of the late Sir Michael Parkinson as the host. The series aims to recreate Parkinson's iconic interview style in conversations with contemporary guests.


2. How does the AI work?

The AI model was developed by Deep Fusion Films. It was trained on thousands of hours of Sir Michael Parkinson's interviews, learning his speech patterns, questioning style, and overall personality. The AI generates new content based on this data, meaning it doesn't simply use snippets of pre-recorded audio.


3. Is this just about using a famous voice for novelty?

While the concept is undeniably attention-grabbing, the podcast has a deeper purpose. It's structured in three parts:

  • Part 1: Discussion about AI and its implications.
  • Part 2: The AI "Michael Parkinson" interviews the guest.
  • Part 3: A reflection on the experience of being interviewed by an AI.

The goal is to explore the evolving nature of human-AI interaction, using the familiar format of a Parkinson interview as a framework.


4. What are the ethical considerations?

The creators are very aware of the ethical complexities of this project. They emphasize four key principles:

  • Informed Consent: The project is fully supported by Michael Parkinson's family and estate.
  • Licensed Data: All training data is legally obtained and licensed.
  • Equal Remuneration: The estate receives fair compensation for the use of Parkinson's likeness.
  • No Passing Off: The podcast clearly identifies the host as an AI replica.

5. How do guests interact with the AI?

The interview is conducted live. The guest hears the AI's questions through headphones and responds in real time, creating a dynamic conversation.


6. Is this a threat to human jobs in the entertainment industry?

The creators argue that this project actually generates jobs. It requires a team of AI specialists, producers, sound engineers, and more to function. It also highlights the potential for AI to enhance and evolve creative processes rather than simply replacing humans.


7. Why is the podcast being made?

There are several motivations:

  • Tribute to Sir Michael Parkinson: The project is seen as a way to honor his legacy and introduce his work to a new generation.
  • Exploration of AI: The podcast provides a platform to discuss and examine the impact of AI on society and human interaction.
  • Entertainment: The creators believe the format can be engaging and thought-provoking for listeners.

8. When and where can I listen to "Virtually Parkinson"?

The podcast is expected to launch in late 2024. Further details regarding the platform and specific release date are yet to be announced.


##


At Google LM, Two AI Voices Discuss the Story


https://notebooklm.google.com/notebook/48076761-8114-49cb-b395-15fea35c87d6/audio


The above audio link is open access but requries a google sign-in.


Wednesday, November 27, 2024

CMS Policy for Artificial Intelligence in Medicare Advantage Operations

On November 26, 2024, CMS released its Part D and Part C (Medicare Advantage) annual rulemaking proposals   In an earlier blog, I discussed the proposed new coverage of anti-obesity medications (AOM) like Wegovy.   

  • In the same rulemaking, Medicare has a section called, "Ensuring Equitable Access to Medicare Advantage Services - Guardrails for Artificial Intelligence."  
  • It's Section 16 and page 13-14 of the inspection copy, and also pages178-185, 362-372, 724 (creating regulation 422.2) .  
    • Section 16 points directly to Biden Executive Order October 30, 2023 (EO fact sheet).     
    • (See also how HHS interprets Section 1557 of ACA, in the context of AI - here.)
    • See Healthcare Dive here.

Here's how CMS summarizes its own MA/AI policymaking, on page 13 of the inspection copy:

Given the growing use of AI within the healthcare sector, such as, but not limited to, AI-based patient care decision support tools, vision transformer-based AI methods for lung cancer imaging applications, and AI and machine learning based decision support systems in mental health care settings, we believe it is necessary to ensure that the use of AI does not result in inequitable treatment, bias, or both, within the healthcare system, and instead is used to promote equitable access to care and culturally competent care for all enrollees. 

As such, we propose to revise § 422.112(a)(8) to ensure services are provided equitably irrespective of delivery method or origin, whether from human or automated systems. 

We also clarify that in the event that an MA plan uses AI or automated systems, it must comply with section 1852(b) of the Act and § 422.110(a) and other applicable regulations and requirements and provide equitable access to services and not discriminate on the basis of any factor that is related to the enrollee’s health status.

###

Perhaps the most interesting thing is something that's not said.   The rulemaking is all about AI in Medicare Advantage, and the idea that AI might improve and coordinate health care claims over in Fee for Service Medicare - MACs - seems to be on the far side of the moon as far as CMS is concerned.  Thre's reference to following historic legacy Part A & B LCDs, not any reference to following groundbreaking innovative AI claims processing from Part A & B.

###

The rules regarding AI in medical review are part of a somewhat broader section on transparency in Medicare Advantage medical review (Section U), with potentially burdensome regulations.   The Biden administration, which proposed these rules, knew it would not be around next spring when they are due to be finalized.  

 ###

AI Corner

  • I fed the pages cited above, into Chat GPT 4o, and asked for an analysis.  
    • I then asked for the likely impression being made on an MA plan that uses AI alot.  
    • I then asked for a comment letter to CMS from such a health plan.

Medicare Advantage (MA) Guardrails for Artificial Intelligence (AI) and Automated Systems: Policy Analysis

Overview of the Policy

The Centers for Medicare & Medicaid Services (CMS) has proposed significant updates to Medicare Advantage (MA) policies to regulate the use of Artificial Intelligence (AI) and automated systems. These revisions stem from concerns over potential inequities and discrimination introduced by algorithmic decision-making in healthcare. CMS aims to ensure that AI systems used by MA organizations promote equitable access to care, comply with anti-discrimination laws, and deliver culturally competent services.

Under the proposed rule, MA organizations must:

  1. Ensure equitable delivery of services, irrespective of whether decisions are made by humans or automated systems.
  2. Maintain compliance with existing statutes, such as section 1852(b) of the Social Security Act, which prohibits discrimination based on health status.
  3. Regularly audit and review AI and automated systems to identify and eliminate biases.

This policy applies to all systems defined as "automated systems," which CMS describes as any computational processes—machine learning, statistical modeling, or other AI techniques—capable of influencing decisions, outcomes, or data collection.


Definition of "Automated Systems"

The proposed rule adopts a broad definition of "automated systems" to ensure comprehensive oversight:

  • Definition: Any system, software, or process that uses computational methods (in whole or part) to determine outcomes, assist decisions, inform policies, collect data, or interact with individuals or communities. This includes AI tools for patient care, risk prediction, diagnosis, and resource allocation.
  • Exclusions: Passive computing infrastructure (e.g., web hosting, domain registration, data storage) that does not influence decisions or actions.

This definition emphasizes the potential societal impact of such systems, particularly on vulnerable populations, and aims to mitigate risks of biased or inequitable care delivery.


Key Legal and Policy Implications

As a law professor specializing in healthcare policy, I see this rulemaking as a landmark regulatory effort with both strengths and weaknesses.

Strengths

  1. Addressing Algorithmic Discrimination: CMS acknowledges evidence showing that AI systems can perpetuate bias. For example, studies indicate that incomplete or biased datasets disproportionately impact marginalized groups. By requiring regular audits, CMS aims to prevent such disparities.

  2. Alignment with Broader Equity Goals: This policy aligns with the Biden administration's Executive Orders on racial equity and the "AI Bill of Rights." It ensures that technological advancements in healthcare support, rather than hinder, equity and access.

  3. Accountability for Third-Party Vendors: MA organizations are held responsible for compliance, even when using AI systems developed by third-party vendors. This avoids loopholes where organizations could disclaim responsibility for biases embedded in outsourced tools.

  4. Transparency: The proposed rules include public posting requirements for internal decision-making tools and coverage criteria, enabling beneficiaries, researchers, and policymakers to scrutinize these systems.

  5. Balancing Innovation with Regulation: By focusing on compliance rather than banning AI outright, CMS fosters innovation while safeguarding patient rights.


Weaknesses or Concerns

  1. Broad Scope of Automated Systems: The definition of "automated systems" is intentionally broad, but it may result in overregulation. For example, simpler tools like statistical models could face the same scrutiny as complex AI algorithms, potentially stifling innovation.

  2. Lack of Specificity in Standards: While the policy emphasizes equity and non-discrimination, it lacks detailed benchmarks for auditing or evaluating AI systems. Without clear standards, enforcement may vary widely, leading to inconsistent compliance.

  3. Resource Burden: MA organizations, particularly smaller ones, may struggle to meet the rigorous compliance requirements, such as regular audits and transparency mandates. These requirements may disproportionately favor larger organizations with more resources.

  4. Unclear Enforcement Mechanisms: While CMS outlines penalties for non-compliance, it does not provide detailed enforcement strategies or timelines. This could weaken the rule's efficacy.

  5. Potential for Data Misuse: Publicly posting internal coverage criteria and algorithms could inadvertently reveal proprietary information, raising concerns about data misuse or intellectual property theft.

  6. Lag in Implementation: The policy is set to take effect in 2026. Given the rapid evolution of AI technologies, this timeline may leave gaps in regulation, especially as new, unregulated AI tools emerge.


Broader Implications for the Healthcare System

The proposed rule reflects a pivotal moment in the intersection of healthcare, technology, and civil rights. While it tackles urgent issues related to equity and AI, it also signals a shift in the regulatory landscape:

  • Precedent-Setting: The rule could influence other federal agencies to adopt similar guardrails for AI in sectors like insurance and public health.
  • Global Impact: By aligning with international frameworks like the EU's AI Act, this policy could position the U.S. as a leader in ethical AI governance.
  • Challenging the Private Sector: The rule pushes private insurers to prioritize equity, which may require significant restructuring of existing AI systems.

Conclusion

CMS’s proposed guardrails for AI and automated systems in Medicare Advantage plans mark a critical step toward ensuring fairness in healthcare. By addressing algorithmic discrimination and emphasizing equitable care, CMS seeks to align technological innovation with civil rights principles. However, the policy’s broad scope, lack of specific enforcement mechanisms, and resource burdens present challenges that will require further refinement.

As legal scholars, it is our responsibility to critically assess these developments, ensuring that regulatory frameworks strike the right balance between innovation, equity, and accountability. These policies will likely shape the future of AI governance in the U.S., making this a case study for both healthcare and administrative law.


##

How would a Medicare Advantage plan that is ahead of the curve on using AI in medical review, and health policy, react to the new proposed rule?  

This health plan is excited about the accuracy and cost savings and efficiency of AI in medical benefit coordination and adjucation.  It doesn't want to turn the clock backward.

A Medicare Advantage (MA) plan that is advanced in using AI for medical review and health policy might have a mixed reaction to CMS's proposed rule. While the plan would appreciate the rule's focus on equitable care and transparency, it would likely express concerns about the additional compliance burdens and potential limitations on innovation. Below is a detailed analysis of how such a plan might react and adapt:


Positive Reactions

  1. Validation of AI's Role in Healthcare:

    • The proposed rule formally acknowledges the growing importance of AI in healthcare decision-making. By regulating rather than banning AI, CMS legitimizes the use of AI tools in Medicare Advantage, which aligns with the plan's forward-thinking adoption of technology.
  2. Opportunity to Demonstrate Leadership:

    • An advanced MA plan would see this as a chance to showcase its AI systems as models of compliance, equity, and efficiency. 
    • This could differentiate the plan in the marketplace, attracting beneficiaries who value cutting-edge technology and transparency.
  3. Support for Equity Goals:

    • The plan may support CMS’s emphasis on reducing bias and promoting equitable access. This aligns with broader healthcare goals and could improve patient outcomes, especially for underserved populations. 
    • Additionally, plans which are already committed to addressing algorithmic bias might welcome this push as a way to level the playing field across their competitors.
  4. Potential to Reduce Long-Term Risk:

    • By addressing biases and complying with regulatory requirements now, the plan could avoid future penalties or reputational damage associated with inequitable or discriminatory AI use.

Concerns and Challenges

  1. Compliance and Auditing Burdens:

    • The plan might find the required audits and reviews of AI systems resource-intensive. Regularly assessing algorithms for biases and publishing internal coverage criteria could divert resources from other priorities, such as expanding services or enhancing patient care.
  2. Transparency Requirements:

    • Publicly posting decision-making criteria may reveal proprietary information about the plan’s AI tools, potentially exposing trade secrets or intellectual property to competitors.
  3. Balancing Cost Savings with Equity:

    • While the plan values AI for its efficiency and cost savings, addressing biases in algorithms may reduce some of those efficiencies. For example, eliminating biased data inputs could require retraining AI systems with more diverse, higher-quality datasets, which is expensive and time-consuming.
  4. Increased Oversight of Vendor Systems:

    • If the plan uses third-party AI vendors, it would now be responsible for ensuring those systems comply with CMS regulations. 
    • This adds a layer of complexity, as the plan must audit vendor algorithms and ensure their compliance. [See also my November 14 blog re: other HHS regulations re hospitals rather than health plans.]
  5. Risk of Overregulation:

    • The broad definition of "automated systems" might result in overregulation, creating unnecessary barriers for relatively simple AI tools. The plan might argue for clearer distinctions between different types of AI systems to reduce unnecessary oversight.

Strategic Adjustments

To adapt to the proposed rule, the MA plan would likely undertake the following steps:

  1. Strengthening Compliance Infrastructure:

    • The plan would establish robust systems to audit AI algorithms, document decision-making processes, and ensure compliance with anti-discrimination rules. This could include hiring equity-focused data scientists or compliance experts.
  2. Proactive Transparency:

    • Rather than resisting transparency requirements, the plan might develop user-friendly ways to communicate how AI tools support equitable and efficient care. This could involve creating public-facing materials that explain the algorithms in plain language.
  3. Collaborating with CMS:

    • The plan could actively engage in the public comment process to suggest practical modifications to the rule. For example, it might advocate for clearer standards for identifying and mitigating bias or propose tiered requirements based on the complexity of AI systems.
  4. Enhancing Vendor Oversight:

    • If the plan relies on third-party AI tools, it would establish stricter vendor management protocols, including regular audits and requirements for vendors to provide bias assessment reports.
  5. Marketing the Benefits of AI:

    • The plan could leverage its compliance with the new rules as a marketing point, emphasizing that its AI systems not only save costs but also promote equitable, culturally competent care.
  6. Piloting New AI Models:

    • The plan might pilot alternative AI models or datasets designed to meet CMS equity goals. For instance, using more diverse training datasets or implementing explainable AI tools that provide clear, actionable insights without sacrificing accuracy.

Balanced Position

While the plan may view some aspects of the rule as burdensome, it would likely recognize the long-term benefits of aligning with CMS’s equity and transparency goals. By proactively addressing potential challenges and positioning itself as a leader in responsible AI use, the plan could turn compliance into a competitive advantage.

The key for the MA plan will be to strike a balance between innovation and regulation—leveraging AI’s accuracy and efficiency while meeting CMS’s expectations for equitable, non-discriminatory care delivery.


##

Provide a comment letter on this proposal, written by the SVP for Government Affairs of a large national health plan that is  ahead of the curve in using AI to improve efficiency, care coordination, and claims processing.


Administrator Chiquita Brooks-LaSure
Centers for Medicare & Medicaid Services (CMS)
Department of Health and Human Services
7500 Security Boulevard
Baltimore, MD 21244-1850

Subject: Comments on Proposed Rule CMS-4208-P – Guardrails for Artificial Intelligence and Automated Systems in Medicare Advantage Plans

Dear Administrator Brooks-LaSure,

On behalf of [Health Plan Name], one of the nation’s largest Medicare Advantage (MA) organizations, I am writing to provide comments on the proposed rule CMS-4208-P, which includes new requirements and guardrails for the use of Artificial Intelligence (AI) and automated systems in Medicare Advantage plans.

[Health Plan Name] has been at the forefront of integrating AI into care coordination, medical review, and claims processing. We are committed to using AI responsibly to enhance efficiency, improve member experiences, reduce healthcare costs, and promote equitable care. While we appreciate CMS’s focus on equity and non-discrimination, we are deeply concerned that the proposed policies are overly broad, impose significant compliance burdens, and may inadvertently hinder innovation in ways that are ultimately detrimental to beneficiaries.


General Support for Equity Goals

We share CMS’s commitment to ensuring that all MA beneficiaries receive equitable, culturally competent care. AI has tremendous potential to address disparities by analyzing complex data patterns, identifying gaps in care, and enabling earlier interventions. For example, our AI-powered care coordination tools have flagged undiagnosed chronic conditions among vulnerable populations, connecting members with critical services.

We also support CMS’s emphasis on transparency and accountability. Ensuring beneficiaries and providers understand how decisions are made is essential for building trust in AI tools. However, we believe that the current proposal risks undermining the very goals of efficiency and equity that AI is uniquely equipped to advance.


Key Concerns with the Proposed Rule

  1. Overly Broad Definition of "Automated Systems"
    The proposed definition of "automated systems" as “any system, software, or process that uses computation...to determine outcomes or assist decisions” is too expansive. This definition includes not only advanced AI models but also simpler tools, such as statistical algorithms or basic decision-support systems.

    Recommendation: CMS should refine the definition to distinguish between high-impact AI systems (e.g., machine learning algorithms used for predictive analytics) and low-impact tools (e.g., rule-based decision engines). Tailoring regulatory requirements to the complexity and risk level of the system would prevent unnecessary compliance burdens while maintaining safeguards for equity.

  2. Transparency Requirements Create Intellectual Property Risks
    Requiring plans to publicly disclose internal coverage criteria and the rationale behind AI-based decisions risks exposing proprietary information. Many AI tools rely on advanced, trade-secret algorithms developed at great expense. Public disclosure could inadvertently allow competitors or third parties to reverse-engineer these tools, discouraging future investment in innovative technologies.

    Recommendation: CMS should implement transparency requirements that protect proprietary information while still enabling beneficiaries and stakeholders to understand decision-making. For example, plans could disclose the general principles and objectives of their AI systems without revealing detailed algorithms or training data.

  3. Compliance and Auditing Burdens
    The proposed requirement for ongoing audits of AI systems and data inputs would impose significant administrative and financial burdens on MA organizations, particularly those that already adhere to best practices. These requirements may deter smaller plans from adopting AI tools, reducing competition and innovation.

    Recommendation: CMS should adopt a risk-based approach to audits, focusing compliance efforts on systems with a higher likelihood of bias or inequity. Low-risk systems that have demonstrated accuracy and fairness through initial validation should not require frequent re-auditing.

  4. Stifling Innovation
    By imposing sweeping and ambiguous restrictions on AI, the proposed rule risks discouraging plans from pursuing innovative uses of technology. AI has delivered measurable benefits to our members, including faster claims adjudication, reduced administrative burdens, and proactive care interventions. Over-regulation may slow progress and harm beneficiaries by delaying these advancements.

    Recommendation: CMS should establish a framework that encourages innovation while ensuring accountability. This could include pilot programs or regulatory sandboxes for testing new AI tools under CMS oversight before broader implementation.

  5. Lack of Clarity on Bias Mitigation Standards
    While the rule emphasizes the need to address bias in AI systems, it does not specify how plans should measure or mitigate bias. This creates uncertainty and could lead to inconsistent interpretations of compliance requirements.

    Recommendation: CMS should collaborate with stakeholders to develop clear, evidence-based standards for bias detection and mitigation in AI systems. These standards should include practical guidelines for collecting diverse datasets and conducting fairness testing.


Proposed Path Forward

Rather than treating AI as a potential liability, CMS should embrace its transformative potential. We urge CMS to:

  • Promote Responsible Innovation: Incentivize plans to adopt AI tools that have demonstrated value in improving care delivery and addressing disparities.
  • Encourage Industry Collaboration: Work with MA organizations, technology developers, and researchers to create practical guidelines for AI governance.
  • Adopt Flexible Regulations: Recognize the diversity of AI systems and tailor oversight to their complexity and impact on beneficiaries.

We also recommend that CMS include a phased implementation timeline to allow plans to adapt their AI systems and compliance processes to meet these new requirements.


Conclusion

[Health Plan Name] believes that AI is a critical tool for advancing the goals of the Medicare Advantage program. With the right regulatory framework, AI can drive efficiency, reduce costs, and improve equity for millions of beneficiaries. We urge CMS to refine its proposal to strike a better balance between safeguarding equity and fostering innovation.

We appreciate the opportunity to comment on this important issue and look forward to working with CMS to shape a forward-thinking policy that benefits all stakeholders.

Sincerely,

[Name]
Senior Vice President, Government Affairs
[Health Plan Name]


##

Minor notes.  Above, I abstracted 362-372 on AI in Medical Review; the whole section on that topic, and matching coverage in LCDs NCDs, is 354-372 (Section U, Enhancing Rules for Internal Coverage Criteria.).